hMAPT/hTFR1
Nomenclature
C57BL/6JSmo-Tfrctm1(hTFRC)Mapttm1(hMAPT)Smoc
Cat. NO.
NM-XA-252009
Strain State
Repository Live
Model Description
Validation Data
Fig.1 Detection of human MAPT expression in cortex, hippocampus and thalamus tissues by qPCR. AD-1637701 significantly suppressed human MAPT mRNA expression in the cortex, hippocampus and thalamus of hMAPT/hTFR1 knock-in mice.
14-15-week-old homozygous hMAPT/hTFR1 knock-in mice were treated with aCSF (n=4 females) or AD-1637701 (synthesized according to a patent, n=4 females) by ICV injection. Tissues RNA was extracted on days 14 post-dosing, then cDNA libraries were synthesized by reverse transcription, followed by qPCR with human MAPT and mouse Gapdh primers. Relative expression represents the human MAPT mRNA level relative to its average expression in Group 1 mice. (Mean±SEM, Unpaired t-test, *p<0.05, **p<0.01).
You may also like
Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreShanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
